NICE has issued a number of new and updated guidelines on a range of topics, including COVID-19.
In its series of COVID-19 rapid guidelines, NICE has published NICE Guideline (NG) 186, COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19. This new guideline covers pharmacological prophylaxis for venous thromboembolism in patients being treated for COVID-19 pneumonia. It includes patients receiving treatment in hospital or in a community setting such as a ‘hospital at home’ service or COVID-19 ‘virtual ward’. The guideline applies to all patients with COVID-19 pneumonia, including those who have other conditions. In addition, NICE has updated NG161 COVID-19 rapid guideline: delivery of systemic anticancer treatments. In the updated guideline, NICE has removed the option to defer treatments that prevent long-term complications, and amended guidance on treatments suitable for home delivery. The guideline now also links to a table of NHS England interim treatment regimens during the COVID-19 pandemic, which should be checked for updates.
Regarding non-COVID guidance, NICE has published NG180, Perioperative care in adults, NG181, Rehabilitation for adults with complex psychosis, and NG185, Acute coronary syndromes. NICE has also updated NG12, Suspected cancer: recognition and referral—when to offer faecal testing for colorectal cancer to adults without rectal bleeding has been clarified in the updated guideline. NG125, Surgical site infections: prevention and treatment, has also been updated to add links to the NICE guideline on perioperative care in adults for additional recommendations on intravenous fluids, cardiac monitoring, and blood glucose control in adults. Also, NG100, Rheumatoid arthritis in adults: management, has been updated so that ‘treat to target’ recommendations clarify that multiple disease-modifying anti-rheumatic drugs can be offered one after the other to achieve treatment targets.
Clinical Guideline 134, Anaphylaxis: assessment and referral after emergency treatment, has been updated to include advice on prescribing adrenaline injectors before discharge after emergency treatment.
NICE has also issued the following Technology Appraisals (TAs) guidance:
- TA649—Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
- TA650—Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
- TA656—Siponimod for treating secondary progressive multiple sclerosis
- TA657—Carfilzomib for previously treated multiple myeloma
- TA658—Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma.
NICE has also updated the following TAs:
- TA71—Guidance on the use of coronary artery stents
- TA152—Drug-eluting stents for the treatment of coronary artery disease.